Portfolio company
Dracen Pharmaceuticals
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
2 investors
Sectors
About
This biotech company develops glutamine antagonist drugs to treat lung cancer and solid tumours for patients with specific genetic mutations.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
D2G Oncology
This company develops genomic drug screening platforms and mouse models to identify genotype-specific cancer treatments for healthcare institutions and pharmaceutical researchers.
Enedra Therapeutics Ltd
This company develops precision medicines and biomarkers to treat advanced, genetically heterogeneous cancers for patients with drug-resistant tumours.
Avistone Pharmaceuticals
The company develops and manufactures precision oncology medicines, specifically small-molecule targeted therapies for patients with lung cancer and other solid tumours.
Deuteroncology
This company develops deuterated MET kinase inhibitors for the treatment of lung cancer and other advanced solid tumours.
iDRx
This biopharmaceutical company develops precision combination therapies targeting genetic drivers and resistance mutations for patients with gastrointestinal stromal tumours.
1200 Pharma
This biotechnology firm develops small molecule therapies and drug intellectual property for the treatment of cancer patients.
Kinnate Biopharma
The company develops small molecule kinase inhibitors for patients with difficult-to-treat cancers featuring specific genetic alterations.
KyDo Therapeutics
This company develops covalent-allosteric small molecule inhibitors for the treatment of challenging cancer variants within the oncology sector.